<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24368339</article-id><article-id pub-id-type="pmc">3928516</article-id><article-id pub-id-type="publisher-id">1511</article-id><article-id pub-id-type="doi">10.1007/s00262-013-1511-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests correlate with prognosis in patients with vulvar squamous cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sznurkowski</surname><given-names>Jacek Jan</given-names></name><address><phone>+48-58-3493436</phone><email>jacek.sznurkowski@gumed.edu.pl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>&#x0017b;awrocki</surname><given-names>Anton</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Biernat</surname><given-names>Wojciech</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Oncological Surgery, The Medical University of Gda&#x00144;sk, ul. Smoluchowskiego 17, 80-214 Gda&#x00144;sk, Poland </aff><aff id="Aff2"><label/>Department of Pathology, The Medical University of Gda&#x00144;sk, Gda&#x00144;sk, Poland </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>63</volume><issue>3</issue><fpage>297</fpage><lpage>303</lpage><history><date date-type="received"><day>30</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p>Adaptive immune effectors do not influence prognosis in vulvar squamous cell carcinoma (vSCC). Therefore, we tried to clarify the prognostic role of innate immunity and granzyme B-dependent cytotoxicity as defined by intratumoral infiltrates of natural killer cells (CD56+) and lymphocytes expressing granzyme B (GrB+).</p></sec><sec><title>Methods</title><p>We analyzed 76 primary vSCCs and 35 lymph node metastases that were obtained from 76 patients with a full clinical history. The distribution and density of GrB+ and CD56+ cells within cancer tissues were evaluated by immunohistochemistry and correlated with clinicopathological features, commonly recognized prognostic factors and overall survival (OS).</p></sec><sec><title>Results</title><p>CD56+ cells were mostly detected within the cancer nests, while GrB+ cells were predominant in the tumor stroma. Intraepithelial (IE) CD56+ infiltrates at the primary site were correlated with depth of invasion (<italic>r</italic>&#x000a0;=&#x000a0;0.339, <italic>p</italic>&#x000a0;=&#x000a0;0.003) and recurrence (<italic>r</italic>&#x000a0;=&#x000a0;0.295, <italic>p</italic>&#x000a0;=&#x000a0;0.011), while IE GrB+ infiltrates were correlated with tumor grade (<italic>r</italic>&#x000a0;=&#x000a0;0.304, <italic>p</italic>&#x000a0;=&#x000a0;0.009) and age (<italic>r</italic>&#x000a0;=&#x000a0;0.333, <italic>p</italic>&#x000a0;=&#x000a0;0.004). The primary cancer nests of metastatic patients were infiltrated more by intraepithelial (IE) CD56+ cells than were those of the non-metastatic patients (<italic>p</italic>&#x000a0;=&#x000a0;0.05). The median OS was 41.16&#x000a0;months (range 1.7&#x02013;98.43). High IE GrB+ infiltrates predicted longer OS among patients without metastases (<italic>p</italic>&#x000a0;=&#x000a0;0.028). High IE CD56+ infiltrates were correlated with longer OS in metastatic cases (<italic>p</italic>&#x000a0;=&#x000a0;0.009).</p></sec><sec><title>Conclusion</title><p>The combined cytotoxicity of innate and adaptive immune effectors infiltrating cancer nests (IE GrB+) predicts an improved clinical outcome among non-metastatic vSCC patients. The functional status of prognostic IE CD56+ infiltrates in immune escaped (metastatic) tumors requires further investigation.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vulvar cancer</kwd><kwd>vSCC</kwd><kwd>CD56+</kwd><kwd>Granzyme B</kwd><kwd>Prognosis</kwd><kwd>TILs</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Vulvar cancer has an incidence of 1&#x02013;2 per 100,000 women per year and represents 3&#x02013;5&#x000a0;% of all gynecological malignancies [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Squamous cell carcinoma (SCC) is the predominant malignancy at this site, accounting for approximately 85&#x02013;90&#x000a0;% of vulvar cancers [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Treatment of advanced stage (FIGO III and IV) vulvar cancer patients may be ineffective, even with chemotherapy and radiotherapy [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, new approaches are required including immunotherapy and greater knowledge of the factors influencing prognosis.</p><p>Tumor infiltrating lymphocytes (TILs) are considered to be a manifestation of the host immune response against cancer cells [<xref ref-type="bibr" rid="CR8">8</xref>]. CD8&#x000a0;+&#x000a0;lymphocytes represent an important subpopulation of cytotoxic T lymphocytes and are the most likely effector TILs of adaptive anti-tumor immunity [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Innate anti-tumor immunity is mediated by cells or soluble factors that naturally exist in the tumor microenvironment. Among hematopoietic cells, natural killer (NK) (CD3&#x02212;CD56+) and NK/T (CD3+CD56+) cells have the natural ability to eliminate tumor-cell targets [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>The cytotoxic function of all immune cells critically depends on serine proteases known as granzymes. As granzyme B is one of the most abundant granzymes, granzyme B-mediated cytotoxicity has been intensively studied [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p>GrB-induced cell death has traditionally been viewed as a primary mechanism that is used by adaptive (CD8+) as well as innate (NK/NKT) effectors to eliminate harmful target cells including tumor cells [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Recently, the status of adaptive immunity represented by CD8+, CD4+ and FOXP3+ T cells was found to lack prognostic significance in vSCC [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, the purpose of this study was to clarify the prognostic roles of innate immune effectors represented by CD56+ cells and granzyme B-dependent cytolysis.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p>This retrospective study was approved by the Polish Ministry of Science and Higher Education review board. The board determined that further informed consent was not required, as all patients provided informed consent for tissue sampling prior to surgical treatment, including written consent for the storage of their information in the hospital database and the use of their information for research.</p><sec id="Sec3"><title>Patients and specimens</title><p>This study included 76 patients with verified histopathological data and full clinical histories. The clinico-pathological characteristics of this group were carefully described in our two previous manuscripts (section: materials and methods) analyzing the expression of indoleamine 2,3-dioxygenase (IDO) and the infiltration of CD8+, CD4+ and FOXP3+ T lymphocytes in vSCC [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The median age of the patients was 69.5&#x000a0;years (range 36&#x02013;85), the median duration of follow-up was 51.23&#x000a0;months (range 6.33&#x02013;135.5), and the median overall survival was 41.16&#x000a0;months (range 1.7&#x02013;98.43) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The immunohistochemical staining and histological analyses were performed on paraffin-embedded material consisting of 76 primary tumors and additional lymph node metastases from 35 patients.</p></sec><sec id="Sec4"><title>Antibodies</title><p>A mouse anti-human monoclonal antibody against CD56 (cat. No NCL-CD56-1B; concentration 1:400) and a mouse anti-human polyclonal antibody against Granzyme B (cat. No 760-4283; ready to use) were obtained from Ventana Medical Systems, Inc.</p></sec><sec id="Sec5"><title>Immunohistochemistry</title><p>The immunohistochemical staining for CD56 and GrB was performed according to the following protocol. Serial sections with a thickness of 4&#x000a0;&#x003bc;m were cut, deparaffinized and subjected to a heat-induced epitope retrieval step before incubation with the primary antibodies. Sections were immersed in target retrieval solution (pH 6.0 for CD56, Dako Cytomation, Denmark) and heated in a pressure cooker. The slides were incubated for 90&#x000a0;min with the primary antibodies.</p><p>The reaction was visualized by the Novolink Polymer Detection System (Novocastra Laboratories). Appropriate positive (normal CD56 and GrB status) and negative controls (the primary antibody was replaced with normal mouse IgG at an appropriate dilution) were included for each case. The immunohistochemical results were evaluated by two independent pathologists who did not have access to the clinical data.</p></sec><sec id="Sec6"><title>Evaluation and classification of CD56+ and GrB+ cells</title><p>The degree of immune cell infiltration was determined for more than 10 high-power (&#x000d7;400) microscopic fields for each tissue sample. Then, five areas with the densest lymphocyte distribution (hot spots) were selected and microphotographs were taken. The quantitative analysis was performed with Multiscan 14.2 software. The numbers of CD56+ and GrB+ cells were counted exclusively within the primary tumor cancer cell nest. For each case, the mean index of CD56+ and GrB+ cells per single high-power field was counted and then statistically analyzed.</p><p>Patients were divided into CD56 low- and high-intensity groups (low CD56+ and high CD56+, respectively) and GrB low- and high-intensity groups (low GrB+ and high GrB+, respectively) based on median cell number (cut-off point) to determine differences in overall survival among these groups [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>The statistical analysis was performed using the chi-square test or Fisher&#x02019;s exact probability test, followed by the Kruskal&#x02013;Wallis test. Correlations and differences between variables were assessed using the Spearman&#x02019;s rank correlation coefficient.</p><p>Overall survival curves were estimated by the Kaplan&#x02013;Meier method and compared by the two-sided log-rank test.</p><p><italic>p</italic> values &#x0003c;0.05 were regarded as significant in all analyses. All analyses were performed using the statistical software Statistica 10 (Stat Soft Inc.).</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Immunohistochemistry for GrB+ cells</title><p>GrB+ cells were predominantly detected in the tumor stroma. They were less abundant within the cancer cell nests (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). For further study, the intraepithelial cell index was assessed.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Microphotograph of immunohistochemical staining for CD56+ cells (<bold>a</bold>) and GrB+ cells (<bold>b</bold>) within the primary cancer nest</p></caption><graphic xlink:href="262_2013_1511_Fig1_HTML" id="MO1"/></fig></p><p>The median number of IE GrB+ cells was 3 (range 0.00&#x02013;13.33) per single high-power field (HPF). Patients in the advanced stage of the disease (35 metastatic cases) and in the locally limited stage (41 non-metastatic cases) had primary cancer nests that were similarly infiltrated by (IE) GrB+ cells (median 3.17 vs. 2.63, <italic>p</italic>&#x000a0;=&#x000a0;0.07).</p><p>In 11 cases, no IE GrB+ cells were observed (14.47&#x000a0;%, GrB-negative tumors).</p><p>GrB-negative tumors exhibited a higher degree of morphological differentiation and were less frequently associated with lymph node metastases (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Comparison of clinicopathological features between patients having primary tumors negative and positive for GrB+ as well as CD56+ cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathological feature</th><th align="left" colspan="2">IE GRB</th><th align="left" rowspan="2">
<italic>p</italic>
</th><th align="left" colspan="2">IE CD56</th><th align="left" rowspan="2">
<italic>p</italic>
</th></tr><tr><th align="left">Negative (<italic>n</italic>&#x000a0;=&#x000a0;11)</th><th align="left">Positive (<italic>n</italic>&#x000a0;=&#x000a0;61)</th><th align="left">Negative (<italic>n</italic>&#x000a0;=&#x000a0;10)</th><th align="left">Positive (<italic>n</italic>&#x000a0;=&#x000a0;65)</th></tr></thead><tbody><tr><td align="left">Age /median/</td><td align="left">62</td><td align="left">70</td><td align="left">0.134</td><td align="left">74</td><td align="left">69</td><td align="left">0.554</td></tr><tr><td align="left">depth of invasion /median/</td><td align="left">6</td><td align="left">7.03</td><td align="left">0.204</td><td align="left">6.63</td><td align="left">7</td><td align="left">0.291</td></tr><tr><td align="left">G1/G2&#x000a0;+&#x000a0;G3</td><td align="left">8/3</td><td align="left">16/45</td><td align="left">
<bold>0.049</bold>
</td><td align="left">4/6</td><td align="left">22/43</td><td align="left">0.731</td></tr><tr><td align="left">G1/G2/G3</td><td align="left">8/1/2</td><td align="left">16/28/17</td><td align="left">
<bold>0.009</bold>
</td><td align="left">4/3/3</td><td align="left">22/26/17</td><td align="left">0.832</td></tr><tr><td align="left">pT</td><td align="left">10/1/0</td><td align="left">55/5/1</td><td align="left">0.909</td><td align="left">8/2/0</td><td align="left">60/4/1</td><td align="left">0.306</td></tr><tr><td align="left">meta+/meta&#x02212;</td><td align="left">2/9</td><td align="left">32/29</td><td align="left">
<bold>0.05</bold>
</td><td align="left">5/5</td><td align="left">29/36</td><td align="left">1.0</td></tr><tr><td align="left">FIGO stage I/II/III/IV</td><td align="left">8/1/2/0</td><td align="left">28/1/28/4</td><td align="left">0.130</td><td align="left">4/1/4/1</td><td align="left">35/1/26/3</td><td align="left">0.374</td></tr><tr><td align="left">recurrence +/&#x02212;</td><td align="left">1/10</td><td align="left">14/47</td><td align="left">0.439</td><td align="left">2/8</td><td align="left">13/52</td><td align="left">1.0</td></tr><tr><td align="left">Overall survival</td><td align="left"/><td align="left"/><td align="left">ns</td><td align="left"/><td align="left"/><td align="left">ns</td></tr></tbody></table><table-wrap-foot><p>Bold values indicate statistical significance</p></table-wrap-foot></table-wrap></p><p>The median number of GrB+ cells infiltrating lymph node metastases was 0.83 (range 0.00&#x02013;8.33). A lack of intracarcinomatous GrB+ cells in nodal metastases was observed in 6 of 28 cases (21.43&#x000a0;%), whereas the primary tumors from these patients contained IE GrB+ cells. The lack of GrB+ cells within metastases does not influence overall survival (<italic>p</italic>&#x000a0;=&#x000a0;0.512).</p></sec><sec id="Sec10"><title>Immunohistochemistry for CD56+ cells</title><p>CD56+ T cells were detected within cancer cell nests and sporadically in the mesenchymal stroma (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b).</p><p>The median number of (IE) CD56+ cells was 2 (range 0.00&#x02013;37) per single high-power field (HPF). Patients in the advanced stage of the disease (35 metastatic cases) had primary cancer nests that were more infiltrated by (IE) CD56+ cells than patients in the locally limited stage (41 non-metastatic cases) (median 2 vs. 1.67, <italic>p</italic>&#x000a0;=&#x000a0;0.05).</p><p>A lack of IE CD56+ infiltrates was observed in 10 of 76 cases (13.16&#x000a0;%). This group did not correspond with the GrB-negative patients described above.</p><p>No differences were observed in all compared clinicopathological features between cases with and without (IE) CD56+ infiltrates (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p>The median number of CD56+ T cells infiltrating lymph node metastases was 1.16 (range 0.00&#x02013;10). A lack of CD56+ infiltrates within nodal metastases was observed in 8 of 35 cases (22.86&#x000a0;%). Only 2 patients had primary nests that were not infiltrated by IE CD56+ cells.</p><p>The lack of CD56+ cells in lymph node metastases had no impact on overall survival (<italic>p</italic>&#x000a0;=&#x000a0;0.3012).</p></sec><sec id="Sec11"><title>Correlation of IE CD56+ and IE GrB+ cells with clinicopathological features</title><p>The number of IE CD56+ (per HPF) was correlated with the depth of invasion and recurrence, while the intensity of the IE GrB+ lymphocytes was correlated with age and tumor grade based on a 2-tier scale: G1 versus G2&#x000a0;+&#x000a0;G3 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Correlation of IE CD56+ and IE GrB+ infiltrates with clinicopathological features of vSCC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinicopathological feature</th><th align="left">IE CD56+</th><th align="left">
<italic>p</italic>
</th><th align="left">IE GzB+</th><th align="left">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;&#x02212;0.126</td><td char="." align="char">0.280</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.333</td><td char="." align="char">
<bold>0.004</bold>
</td></tr><tr><td align="left">pT</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.001</td><td char="." align="char">0.992</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.021</td><td char="." align="char">0.862</td></tr><tr><td align="left">depth of invasion</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.339</td><td char="." align="char">
<bold>0.003</bold>
</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.196</td><td char="." align="char">0.102</td></tr><tr><td align="left">G1/G2/G3</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.023</td><td char="." align="char">0.849</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.207</td><td char="." align="char">0.080</td></tr><tr><td align="left">G1/G2&#x000a0;+&#x000a0;G3</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.093</td><td char="." align="char">0.432</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.304</td><td char="." align="char">
<bold>0.009</bold>
</td></tr><tr><td align="left">pN</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.222</td><td char="." align="char">0.057</td><td align="left">0.216</td><td char="." align="char">0.069</td></tr><tr><td align="left">FIGO stage I/II/III/IV</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.208</td><td char="." align="char">0.075</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.226</td><td char="." align="char">0.056</td></tr><tr><td align="left">recurrence +/&#x02212;</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;&#x02212;0.295</td><td char="." align="char">
<bold>0.011</bold>
</td><td align="left">
<italic>r</italic>&#x000a0;=&#x000a0;0.109</td><td char="." align="char">0.362</td></tr></tbody></table><table-wrap-foot><p>Bold values indicate statistical significance</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Prognostic significance of IE GrB+ cells at the primary site</title><p>Patients were divided into GrB low- and high-intensity groups (low GrB+ and high GrB&#x000a0;+, respectively) based on the median value of IE GrB+ cells.</p><p>With the exception of age (high GrB+ patients were older than low GrB+ patients), no differences were observed between groups in the pathological features analyzed here (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Differences in clinicopathological features between patients having primary tumors infiltrated with low and high numbers of intraepithelial GrB+ and CD56+ cells (median as a cutoff point)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinicopathological feature</th><th align="left">Low (IE)GrB+</th><th align="left">High (IE)GRB+</th><th align="left">p</th><th align="left">Low (IE)CD56+</th><th align="left">High (IE)CD56+</th><th align="left">p</th></tr></thead><tbody><tr><td align="left">Age /median/</td><td align="left">65</td><td align="left">71</td><td char="." align="char">
<bold>0.011</bold>
</td><td align="left">69</td><td align="left">69</td><td char="." align="char">0.996</td></tr><tr><td align="left">depth of invasion /median/</td><td align="left">7</td><td align="left">7.4</td><td char="." align="char">0.355</td><td align="left">6.25</td><td align="left">7.75</td><td char="." align="char">0.01</td></tr><tr><td align="left">G1/G2/G3</td><td align="left">15/9/8</td><td align="left">9/20/11</td><td char="." align="char">0.070</td><td align="left">17/15/13</td><td align="left">9/14/7</td><td char="." align="char">0.509</td></tr><tr><td align="left">G1/G2&#x000a0;+&#x000a0;G3</td><td align="left">15/17</td><td align="left">9/31</td><td char="." align="char">0.044</td><td align="left">17/28</td><td align="left">9/21</td><td char="." align="char">0.622</td></tr><tr><td align="left">pT</td><td align="left">30/1/1</td><td align="left">35/5/0</td><td char="." align="char">0.202</td><td align="left">41/3/1</td><td align="left">27/3/0</td><td char="." align="char">0.632</td></tr><tr><td align="left">meta+/meta&#x02212;</td><td align="left">12/20</td><td align="left">22/18</td><td char="." align="char">0.161</td><td align="left">17/28</td><td align="left">17/13</td><td char="." align="char">0.155</td></tr><tr><td align="left">FIGO stage I/II/III/IV</td><td align="left">19/1/11/1</td><td align="left">17/1/19/3</td><td char="." align="char">0.496</td><td align="left">27/1/15/2</td><td align="left">12/1/15/2</td><td char="." align="char">0.410</td></tr><tr><td align="left">recurrence +/&#x02212;</td><td align="left">5/27</td><td align="left">10/30</td><td char="." align="char">0.392</td><td align="left">5/40</td><td align="left">10/20</td><td char="." align="char">0.036</td></tr></tbody></table><table-wrap-foot><p>Bold values indicate statistical significance</p></table-wrap-foot></table-wrap></p><p>While no differences in overall survival (OS) were observed between high GrB+ and low GrB+ cases in the general cohort (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) (F Cox <italic>p</italic>&#x000a0;=&#x000a0;0.479), more IE GrB+ cells than the median were correlated with longer OS among cases with local disease (F Cox <italic>p</italic>&#x000a0;=&#x000a0;0.028) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Kaplan&#x02013;Meier survival curves for overall survival of patients. <bold>a</bold> low CD56+/high CD56+ infiltrates within cancer nests in the general population. <bold>b</bold> low CD56+/high CD56+ infiltrates within cancer nests in metastatic cases. <bold>c</bold> low GrB+/high GrB+ infiltrates within cancer nests in the general population. <bold>d</bold> low GrB+/high GrB+ infiltrates within cancer nests in non-metastatic cases</p></caption><graphic xlink:href="262_2013_1511_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Prognostic significance of IE CD56+ cells at the primary site</title><p>Patients were divided into CD56 low- and high-intensity groups (low CD56+ and high CD56+, respectively) based on the median value of IE CD56+ cells.</p><p>No differences were observed in all analyzed clinico-pathological features among different CD56 infiltration categories in our cohort (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p>While no differences in overall survival were observed between these groups in the general cohort (F Cox <italic>p</italic>&#x000a0;=&#x000a0;0.141) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c), intensities of IE CD56+ cells exceeding the median (high-CD56+) were correlated with longer OS among patients with metastatic dissemination (F Cox <italic>p</italic>&#x000a0;=&#x000a0;0.009) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d).</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>The distribution of CD56+ cells and GrB expressing cells at the primary site differed in the vSCC cases analyzed here. CD56+ cells were mostly detected within the cancer nests, while the GrB+ cells were predominant in the tumor stroma. Only activated cytotoxic lymphocytes and NK/NKT cells are able to express granzyme B [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The higher stromal distribution of GrB+ cells suggests that the vast majority of immune effectors are activated outside the cancer nests, chiefly through mechanisms unrelated to the recognition of vSCC antigens.</p><p>Moreover, the large discrepancy between IE GrB&#x000a0;+&#x000a0;infiltrates (median 3) and the cumulative number of intraepithelial immune effectors (median 2 for IE CD56+ and median 19 for IE CD8+ infiltrates) recently described by our group for this cohort [<xref ref-type="bibr" rid="CR14">14</xref>] could suggest that the cytolytic power of the immune system has been lost outside rather than inside cancer nests.</p><p>This could explain the lack of prognostic significance of CD8+ lymphocytes in vSCC [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and suggests that the number of TILs present in the stroma probably provides a better indication of coexisting inflammatory processes than the immunogenicity of cancer cells.</p><p>In contrast, TILs within cancer nests are certainly connected with direct spontaneous immune reactions against cancer [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], and therefore, only these intraepithelial infiltrates (IE) were analyzed further.</p><p>We found that the median numbers of IE GrB+ and IE CD56+ cells were comparable (3 and 2 per HPF within the primary cancer nest and 0.83 and 1.016 per HPF within lymph node metastases, respectively). This could suggest that these cells are the same cells, but considering the current results together with our previous data on IE CD8+ T lymphocytes in this cohort [<xref ref-type="bibr" rid="CR14">14</xref>], we believe that only a small subset of IE CD56+ cells could be granzyme B positive.</p><p>This is supported by further results indicating that IE CD56+ and IE GrB+ infiltrates have separate correlations with clinico-pathological features in patients with vSCC.</p><p>The intensity of IE CD56+ cells was significantly correlated with depth of invasion and recurrence, while the intensity of IE GrB+ lymphocytes was correlated with age and tumor grade.</p><p>Patients in the advanced stage of the disease had primary cancer nests that were more infiltrated by IE CD56+ cells than cases in the locally limited stage. This was not observed for IE GrB+ infiltrates. These data could suggest that IE CD56+ infiltrates coincide with more aggressive tumors.</p><p>However, neither high IE CD56+ nor high IE GrB+ infiltrates had an impact on overall survival in vSCC patients. Further, to analyze the prognostic significance of these cells, we decided to subdivide the cohort into 2 groups: non-metastatic and metastatic. From the immunological point of view, patients with local and disseminated disease represent unsuccessful and successful immune escape, respectively [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, subdividing the general cohort into these two subtypes and conducting separate survival analyses seems to be justified.</p><p>High IE GrB+ infiltrates were correlated with longer OS in non-metastatic cases. It is unclear whether the immune surveillance performed by the cytotoxic function of the activated effectors of adaptive (CD8+ T cells) and innate (NK/NKT cells) immunity is efficient until tumors develop mechanisms of immune escape. Various proportions of the adaptive and innate effectors could be involved in granzyme B-dependent cytotoxicity because of the diverse expression of MHC antigens, costimulatory molecules and antigen-presenting cell (APC) statuses in different cancers, as well as the different number of regulatory cells within tumor tissue [<xref ref-type="bibr" rid="CR23">23</xref>]. This could explain why the effectors of adaptive (CD8+) immunity did not reveal prognostic significance when analyzed separately [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Natural killer cells are considered to play a major role in the early stages of tumor development [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Previous reports showed that while innate immunity represents the first line of pathogen defense [<xref ref-type="bibr" rid="CR26">26</xref>], most human tumor cells are resistant to perforin-mediated NK cell lysis, and NK cells are rarely found among TILs in advanced cancer cases [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Interestingly, the correlation between the intensity of IE CD56+ (NK/NKT) cells and survival was observed among metastatic vSCC patients, while the prognostic significance of granzyme B-dependent killing was not observed in this subgroup. Either these immune cells defending against metastases have already released GrB and are now GrB(&#x02212;), or they represent a distinct subset of NK/NKT cells mediating tumor destruction by mechanisms other than GrB-mediated cytotoxicity. The second concept is consistent with more recent data suggesting that the primary biological role of NKs might not be the elimination of tumor targets, but rather the facilitation of dendritic-cell (DC)&#x02013;T-cell interactions. As a consequence, this process may drive the immune responses against tumor-associated antigens (TAAs) [<xref ref-type="bibr" rid="CR27">27</xref>]. This hypothesis could be supported by the fact that a diminished infiltration of CD4+ T cells is observed among advanced vSCC cases (authors&#x02019; unpublished data). CD4+ T-cell-deficient intratumoral infiltrates may impair the adaptive immune response, which is primarily regulated by DCs.</p><p>Recent data suggest that in addition to granzyme-mediated lysis, NK/NKT cells constitutively express several ligands of the TNF-family and can induce apoptosis in a broad variety of tumor-cell targets [<xref ref-type="bibr" rid="CR28">28</xref>]. This mechanism might be of greater biological importance than secretory, granule-mediated killing, largely because of the expression of TNF-family ligands by tumor cells resulting in their sensitivity to apoptotic death [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Interestingly, patients with disseminated cancer were significantly older than patients without metastases in the cohort analyzed here [<xref ref-type="bibr" rid="CR15">15</xref>]. It is known that immune anti-tumor responses can be influenced by the gradual deterioration of the immune system with age [<xref ref-type="bibr" rid="CR10">10</xref>]. A significant expansion in the number of NK cells was observed upon aging [<xref ref-type="bibr" rid="CR30">30</xref>], but some controversy remains concerning the efficacy of their cytotoxic function, which has been described as comparable to [<xref ref-type="bibr" rid="CR31">31</xref>] or decreased [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] compared with younger individuals.</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusion</title><p>IE GrB+ infiltrates, which indicate the cytolytic power of combined adaptive and innate immune effectors, and IE CD56+ infiltrates, which indicate NK/NKT cells of unknown functional status, correlate with longer OS among non-metastatic and metastatic vSCC cases, respectively.</p><p>Both of these significant results suggest that immunological effects contribute to improved clinical outcomes in vSCC.</p></sec></body><back><ack><p>This work was supported by the Polish Ministry of Science and Higher Education Grant no. N 40306631/3077 to Jacek Jan Sznurkowski, and Internal University Funding ST 95.</p><sec id="d30e1382"><title>Conflict of interest</title><p>The authors have contributed to read and approved this manuscript and declare that there are no conflicts of interest to be disclosed.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturgeon</surname><given-names>SR</given-names></name><name><surname>Bronton</surname><given-names>LA</given-names></name><name><surname>Devesa</surname><given-names>SS</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>In situ and invasive vulvar cancer incidence trends (1973&#x02013;1987)</article-title><source>Am J Obstet Gynecol</source><year>1992</year><volume>166</volume><issue>5</issue><fpage>1482</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1016/0002-9378(92)91623-I</pub-id><pub-id pub-id-type="pmid">1595803</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansink</surname><given-names>AC</given-names></name><name><surname>Heintz</surname><given-names>AP</given-names></name></person-group><article-title>Epidemiology and etiology of squamous cell carcinoma of the vulva</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>1993</year><volume>48</volume><issue>2</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/0028-2243(93)90250-G</pub-id><pub-id pub-id-type="pmid">8387937</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>J</given-names></name><name><surname>Gleeson</surname><given-names>N</given-names></name></person-group><article-title>Local and regional recurrence of vulval cancer: management dilemmas</article-title><source>Best Pract Res Clin Obstet Gynaecol</source><year>2003</year><volume>17</volume><issue>4</issue><fpage>663</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/S1521-6934(03)00050-6</pub-id><pub-id pub-id-type="pmid">12965138</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Monaghan</surname><given-names>JM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Shepherd</surname><given-names>JH</given-names></name><name><surname>Monaghan</surname><given-names>JM</given-names></name></person-group><article-title>The management of carcinoma of the vulva</article-title><source>Clinical gynecologiconcology</source><year>1990</year><edition>2</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Blackwell</publisher-name><fpage>140</fpage><lpage>167</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beller</surname><given-names>U</given-names></name><name><surname>Quinn</surname><given-names>MA</given-names></name><name><surname>Benedet</surname><given-names>JL</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Ngan</surname><given-names>HY</given-names></name><name><surname>Maisonneuve</surname><given-names>P</given-names></name><name><surname>Pecorelli</surname><given-names>S</given-names></name><name><surname>Odicino</surname><given-names>F</given-names></name><name><surname>Heintz</surname><given-names>AP</given-names></name></person-group><article-title>Carcinoma of the vulva FIGO 26th annual report on the results of treatment in gynecological cancer</article-title><source>Int J Gynaecol Obstet.</source><year>2006</year><volume>95 Suppl 1</volume><fpage>S7</fpage><lpage>S27</lpage><pub-id pub-id-type="doi">10.1016/S0020-7292(06)60028-3</pub-id><pub-id pub-id-type="pmid">17161169</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggino</surname><given-names>T</given-names></name><name><surname>Landoni</surname><given-names>F</given-names></name><name><surname>Sartori</surname><given-names>E</given-names></name><name><surname>Zola</surname><given-names>P</given-names></name><name><surname>Gadducci</surname><given-names>A</given-names></name><name><surname>Alessi</surname><given-names>C</given-names></name><name><surname>Sold&#x000e0;</surname><given-names>M</given-names></name><name><surname>Coscio</surname><given-names>S</given-names></name><name><surname>Spinetti</surname><given-names>G</given-names></name><name><surname>Maneo</surname><given-names>A</given-names></name><name><surname>Ferrero</surname><given-names>A</given-names></name><name><surname>Konishi De Toffoli</surname><given-names>G</given-names></name></person-group><article-title>Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study</article-title><source>Cancer</source><year>2000</year><volume>89</volume><issue>1</issue><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20000701)89:1&#x0003c;116::AID-CNCR16&#x0003e;3.0.CO;2-4</pub-id><pub-id pub-id-type="pmid">10897008</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadducci</surname><given-names>A</given-names></name><name><surname>Cionini</surname><given-names>L</given-names></name><name><surname>Romanini</surname><given-names>A</given-names></name><name><surname>Fanucchi</surname><given-names>A</given-names></name><name><surname>Genazzani</surname><given-names>AR</given-names></name></person-group><article-title>Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2006</year><volume>60</volume><issue>3</issue><fpage>227</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2006.06.009</pub-id><pub-id pub-id-type="pmid">16945551</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Prognosis in human tumor immunology and immunotherapy</article-title><source>Nature</source><year>2001</year><volume>411</volume><issue>6835</issue><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/35077246</pub-id><pub-id pub-id-type="pmid">11357146</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name></person-group><article-title>Immunity to tumors</article-title><source>Cellular and molecular immunology</source><year>1997</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>WB Saunders</publisher-name><fpage>382</fpage><lpage>405</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provinciali</surname><given-names>M</given-names></name></person-group><article-title>Immunosenescence and cancer vaccines</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><issue>12</issue><fpage>1959</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1007/s00262-009-0665-z</pub-id><pub-id pub-id-type="pmid">19198836</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name><name><surname>Vojanovic</surname><given-names>NL</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name></person-group><article-title>Natural killer cells and tumor therapy</article-title><source>Curr Top Microbiol Immunol</source><year>1998</year><volume>230</volume><fpage>221</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">9586358</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousalova</surname><given-names>I</given-names></name><name><surname>Krepela</surname><given-names>E</given-names></name></person-group><article-title>Granzyme B-induced apoptosis in cancer cells and its regulation (review)</article-title><source>Int J Oncol</source><year>2010</year><volume>37</volume><issue>6</issue><fpage>1361</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">21042704</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>WJ</given-names></name><name><surname>Verbsky</surname><given-names>JW</given-names></name><name><surname>Tollefsen</surname><given-names>BL</given-names></name><name><surname>Kemper</surname><given-names>C</given-names></name><name><surname>Atkinson</surname><given-names>JP</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name></person-group><article-title>Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and Tregulatory cells</article-title><source>Blood</source><year>2004</year><volume>104</volume><issue>9</issue><fpage>2840</fpage><lpage>2848</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-03-0859</pub-id><pub-id pub-id-type="pmid">15238416</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sznurkowski</surname><given-names>JJ</given-names></name><name><surname>Zawrocki</surname><given-names>A</given-names></name><name><surname>Emerich</surname><given-names>J</given-names></name><name><surname>Biernat</surname><given-names>W</given-names></name></person-group><article-title>Prognostic significance of CD4<sup>+</sup> and CD8<sup>+</sup> T cells infiltration within cancer cell nests in vulvar squamous cell carcinoma</article-title><source>Int J Gynecol Cancer</source><year>2011</year><volume>21</volume><issue>4</issue><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1097/IGC.0b013e3182131f36</pub-id><pub-id pub-id-type="pmid">21543933</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sznurkowski</surname><given-names>JJ</given-names></name><name><surname>Zawrocki</surname><given-names>A</given-names></name><name><surname>Emerich</surname><given-names>J</given-names></name><name><surname>Sznurkowska</surname><given-names>K</given-names></name><name><surname>Biernat</surname><given-names>W</given-names></name></person-group><article-title>Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests</article-title><source>Gynecol Oncol</source><year>2011</year><volume>122</volume><issue>2</issue><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2011.04.050</pub-id><pub-id pub-id-type="pmid">21616522</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>RA</given-names></name><name><surname>Toppen</surname><given-names>NL</given-names></name><name><surname>Ten Hoor</surname><given-names>KA</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name><name><surname>Kema</surname><given-names>IP</given-names></name><name><surname>Hollema</surname><given-names>H</given-names></name><name><surname>Nijman</surname><given-names>HW</given-names></name></person-group><article-title>Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma</article-title><source>Gynecol Oncol</source><year>2012</year><volume>125</volume><issue>1</issue><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2011.12.416</pub-id><pub-id pub-id-type="pmid">22155674</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name><name><surname>Ohkuri</surname><given-names>O</given-names></name><etal/></person-group><article-title>Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance</article-title><source>Int J Oncol</source><year>2006</year><volume>28</volume><issue>5</issue><fpage>1089</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">16596224</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>O</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Oizumi</surname><given-names>S</given-names></name><etal/></person-group><article-title>CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell cancers</article-title><source>Cancer Sci</source><year>2003</year><volume>94</volume><issue>11</issue><fpage>1003</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01392.x</pub-id><pub-id pub-id-type="pmid">14611679</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansfield</surname><given-names>AS</given-names></name><name><surname>Heikkila</surname><given-names>PS</given-names></name><name><surname>Vaara</surname><given-names>AT</given-names></name><name><surname>von Smitten</surname><given-names>KA</given-names></name><name><surname>Vakkila</surname><given-names>JM</given-names></name><name><surname>Leidenius</surname><given-names>MH</given-names></name></person-group><article-title>Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer</article-title><source>BMC Cancer</source><year>2009</year><volume>15</volume><issue>9</issue><fpage>231</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-231</pub-id><pub-id pub-id-type="pmid">19604349</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sznurkowski</surname><given-names>JJ</given-names></name></person-group><article-title>Comments on manuscript entitled &#x0201c;Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma&#x0201d; by de Jong RA et al. Gynecol Oncol</article-title><source>Gynecol Oncol</source><year>2012</year><volume>125</volume><issue>3</issue><fpage>767</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.02.036</pub-id><pub-id pub-id-type="pmid">22394649</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">
Sznurkowski JJ (2012) Author&#x02019;s reply; doi: 10.1016/j.ygyno.2012.02.036</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>The tumor microenvironment and its role in promoting tumor growth</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><issue>45</issue><fpage>5904</fpage><lpage>5912</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.271</pub-id><pub-id pub-id-type="pmid">18836471</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonina</surname><given-names>IS</given-names></name><name><surname>Cullen</surname><given-names>SP</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name></person-group><article-title>Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B</article-title><source>Immunol Rev</source><year>2010</year><volume>235</volume><issue>1</issue><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">20536558</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Crowe</surname><given-names>NY</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name></person-group><article-title>NKT cells&#x02014;conductors of tumor immunity?</article-title><source>Curr Opin Immunol</source><year>2002</year><volume>14</volume><issue>2</issue><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(02)00316-3</pub-id><pub-id pub-id-type="pmid">11869887</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name></person-group><article-title>New aspects of natural-killer-cell surveillance and therapy of cancer</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><issue>11</issue><fpage>850</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1038/nrc928</pub-id><pub-id pub-id-type="pmid">12415255</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><article-title>Natural killer cell receptor signaling</article-title><source>Curr Opin Immunol</source><year>2003</year><volume>15</volume><issue>3</issue><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(03)00039-6</pub-id><pub-id pub-id-type="pmid">12787756</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JM</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name><name><surname>Markby</surname><given-names>JL</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Yagitab</surname><given-names>H</given-names></name><etal/></person-group><article-title>Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><issue>1</issue><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/ni746</pub-id><pub-id pub-id-type="pmid">11743585</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vujanovic</surname><given-names>NL</given-names></name><name><surname>NagashimaS</surname><given-names>HR</given-names></name><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>Non-secretory apoptotic killing by human natural killer cells</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><issue>3</issue><fpage>1117</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">8757616</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>Immune responses to malignancies</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>125</volume><issue>2 Suppl 2</issue><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.045</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrego</surname><given-names>F</given-names></name><name><surname>Alonso</surname><given-names>MC</given-names></name><name><surname>Galiani</surname><given-names>MD</given-names></name><name><surname>Carracedo</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>R</given-names></name><name><surname>Ostos</surname><given-names>B</given-names></name><etal/></person-group><article-title>NK phenotypic markers and IL2 response in NK cells from elderly people</article-title><source>Exp Gerontol</source><year>1999</year><volume>34</volume><issue>2</issue><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/S0531-5565(98)00076-X</pub-id><pub-id pub-id-type="pmid">10363791</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutza</surname><given-names>J</given-names></name><name><surname>Murasko</surname><given-names>DM</given-names></name></person-group><article-title>Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples</article-title><source>Mech Ageing Dev</source><year>1996</year><volume>90</volume><issue>3</issue><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/0047-6374(96)01772-1</pub-id><pub-id pub-id-type="pmid">8898314</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>E</given-names></name><name><surname>Roda</surname><given-names>P</given-names></name><name><surname>Mariani</surname><given-names>AR</given-names></name><name><surname>Vitale</surname><given-names>M</given-names></name><name><surname>Degrassi</surname><given-names>A</given-names></name><name><surname>Papa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Age-associated changes in CD8+ and CD16+ cell reactivity: clonal analysis</article-title><source>Clin Exp Immunol</source><year>1990</year><volume>81</volume><issue>3</issue><fpage>479</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.1990.tb05359.x</pub-id><pub-id pub-id-type="pmid">2144486</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name></person-group><article-title>Natural killing and antibody-dependent cytotoxicity by lymphocyte subpopulations in young and aging humans</article-title><source>J Clin Immunol</source><year>1981</year><volume>1</volume><issue>13</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1007/BF00922755</pub-id><pub-id pub-id-type="pmid">6977553</pub-id></element-citation></ref></ref-list></back></article>